https://orcid.org/0000-0002-0489-2611
References
- Bae CB, Jung JY, Kim HA, et al. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features, predictive factors, and prognosis in 21 patients. Medicine (Baltimore). 2015;94(4):e451.
- Gerfaud-Valentin M, Maucort-Boulch D, Hot A, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93(2):91–99.
- Schulert GS, Grom AA. Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol. 2014;28(2):277–292.
- Kaneko Y, Kameda H, Ikeda K, et al. Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018;77(12):1720–1729.
- Faguer S, Vergez F, Peres M, et al. Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8 + Granzyme + T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosis. Hematol Oncol. 2016;34(1):55–57.
- Yokota S, Itoh Y, Morio T, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol. 2015;42(4):712–722.
- Kobayashi M, Takahashi Y, Yamashita H, et al. Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011;21(1):92–96.
- Ohmura SI, Uehara K, Yamabe T, et al. Successful use of short-term add-on tocilizumab for refractory adult-onset still’s disease with macrophage activation syndrome despite treatment with high-dose glucocorticoids, cyclosporine, and etoposide. Mod Rheumatol Case Reports. 2020;4(2):202–206.
- Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–131.
- Maeshima K, Ishii K, Iwakura M, et al. Adult-onset Still's disease with macrophage activation syndrome successfully treated with a combination of methotrexate and etanercept. Mod Rheumatol. 2012;22(1):137–141.
- Naniwa T, Tamechika S, Iwagaitsu S, et al. Successful use of higher-dose etanercept for multirefractory systemic flare of adult-onset Still's disease with liver failure with no response to tocilizumab therapy. Case Rep Rheumatol. 2013;2013:923497.
- Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70(2):118–136.
- Weiss ES, Girard-Guyonvarc’h C, Holzinger D, et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood. 2018;131(13):1442–1455.
- Inoue N, Shimizu M, Tsunoda S, et al. Cytokine profile in adult-onset Still's disease: comparison with systemic juvenile idiopathic arthritis. Clin Immunol. 2016;169:8–13.
- Fujii T, Nojima T, Yasuoka H, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology (Oxford). 2001;40(12):1398–1404.
- Hoshino T, Ohta A, Yang D, et al. Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still’s disease. J Rheumatol. 1998;25:396–398.
- Tilg H, Trehu E, Atkins MB, et al. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994;83(1):113–118.